Brilliant minds at the Center for Biopharmaceuticals are now attempting to rewrite the core function of proteins by making alterations in their molecular backbone, for example. By combining biological and chemical methods, researchers are able to design semi-synthetic proteins with almost no regard to the limitations of nature:
"Proteins can be regulated to perform specific biochemical tasks. We have used a technology that allows us to make changes to the molecular backbone of the protein and have thus created 22 completely new designer proteins on the basis of recognised material. Using advanced chemical-biological methods, we made the minuscule changes to the backbone of one of the most frequently occurring protein domains – a kind of fixed, independent module that features in a range of proteins. We then examined how the designer proteins bind to other proteins in the body, which allowed us to analyse the role of the specific protein domain in the body's vital signal processes," relates Søren W. Pedersen, postdoc.
All the cells in the body communicate via receptor proteins that are located in the cell membrane. This activates proteins inside the cell, causing specific effects which, in turn, stimulate the body to execute a variety of functions.
"Our designer proteins show us precisely how and where a bond is formed. This provides unique molecular understanding of the protein domain and a number of key protein bonds in the organism. For example the designer proteins bind to a range of receptors in the body – receptor interactions that are important targets for pharmaceuticals intended to treat stroke, pain and depression. The new findings mean that in the long term, we will be able to design pharmaceuticals that bind more strongly and more accurately to specific sites in the organism."
The fundamental findings have just been published in the scientific journal Nature Communications.
From 'on/off switch' to 'advanced dimmer'
Pharmaceuticals generally function by binding to a specific receptor that is involved in a given illness process – thus halting the damaging effect. Unfortunately, this strategy often generates side effects as the process simultaneously shuts down a number of beneficial functions. In recent years, interest has therefore arisen in a different strategy in which the pharmaceutical does not affect the receptor directly, but alters the interactions that the receptor has with proteins inside the cell. In other words, instead of simply switching the function of the receptor on and off, the objective is now to control parts of the receptor's effects. It is here that designer proteins can come to play a key role:
"The capacity to manipulate proteins has led to important breakthroughs in biotechnology and biomedicine. Proteins can often target specific processes in the cells with a high degree of accuracy – and at the Center for Biopharmaceuticals we are combining chemical synthesis and biological processes to find out more about the molecular interactions that may be of significance to biological pharmaceuticals," explains Professor Kristian Strømgaard, head of the Center for Biopharmaceuticals at the University of Copenhagen.
Contact:Professor Kristian Strømgaard
It has conventionally been possible to use one of two methods to manufacture human proteins in the laboratory. The first method is biological and involves using gene technology to introduce the gene into single-cell organisms such as bacteria and yeast, or into mammal cells. The alternative is to create a protein chemically, which involves linking the amino acids together one by one until the required peptide or protein has been formed.
Each technology has its advantages and drawbacks. The production of proteins in bacteria and yeast is relatively simple to escalate to industrial scale, but gene technology is limited to the use of the 20 amino acids for which the genes code. The chemical method is not limited to the 20 amino acids, but it is expensive and can only be used to make small proteins containing up to 50 amino acids. Most of the 20,000 proteins in the human body are much larger.
Researchers at the Center for Biopharmaceuticals are combining biology and chemistry to make semi-synthetic proteins. This approach entails making only a part of the protein in bacteria or yeast, while the remaining part is created using chemical synthesis. The two sections are then 'glued together' to form the final designer protein.
Kristian Strømgaard | EurekAlert!
First SARS-CoV-2 genomes in Austria openly available
03.04.2020 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften
Do urban fish exhibit impaired sleep? Light pollution suppresses melatonin production in European perch
03.04.2020 | Leibniz-Institut für Gewässerökologie und Binnenfischerei (IGB)
Drops of water falling on or sliding over surfaces may leave behind traces of electrical charge, causing the drops to charge themselves. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz have now begun a detailed investigation into this phenomenon that accompanies us in every-day life. They developed a method to quantify the charge generation and additionally created a theoretical model to aid understanding. According to the scientists, the observed effect could be a source of generated power and an important building block for understanding frictional electricity.
Water drops sliding over non-conducting surfaces can be found everywhere in our lives: From the dripping of a coffee machine, to a rinse in the shower, to an...
90 million-year-old forest soil provides unexpected evidence for exceptionally warm climate near the South Pole in the Cretaceous
An international team of researchers led by geoscientists from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) have now...
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply. When the iron transport into the bacteria is inhibited, the pathogen can no longer grow. This opens novel ways to develop targeted tuberculosis drugs.
One of the most devastating pathogens that lives inside human cells is Mycobacterium tuberculosis, the bacillus that causes tuberculosis. According to the...
An international team with the participation of Prof. Dr. Michael Kues from the Cluster of Excellence PhoenixD at Leibniz University Hannover has developed a new method for generating quantum-entangled photons in a spectral range of light that was previously inaccessible. The discovery can make the encryption of satellite-based communications much more secure in the future.
A 15-member research team from the UK, Germany and Japan has developed a new method for generating and detecting quantum-entangled photons at a wavelength of...
Together with their colleagues from the University of Würzburg, physicists from the group of Professor Alexander Szameit at the University of Rostock have devised a “funnel” for photons. Their discovery was recently published in the renowned journal Science and holds great promise for novel ultra-sensitive detectors as well as innovative applications in telecommunications and information processing.
The quantum-optical properties of light and its interaction with matter has fascinated the Rostock professor Alexander Szameit since College.
02.04.2020 | Event News
26.03.2020 | Event News
23.03.2020 | Event News
03.04.2020 | Materials Sciences
03.04.2020 | Life Sciences
03.04.2020 | Life Sciences